source
- Cullinan-Taiho eye FDA filing for zipalertinib after trial shows strong PFS benefit despite three deathsCullinan Therapeutics and its partner Taiho Oncology said they will seek FDA approval for zipalertinib, an oral therapy for a subset of non‑small cell lung cancer, based on data from a late‑stage s…
- FDA opens pilot to accelerate phase 1 trials with fast IND reviewsThe Food and Drug Administration announced a new pilot program aimed at speeding up early-stage clinical trials in the United States. The initiative pairs drug sponsors with qualified research inst…